Background
==========

There are over 100 point mutations putatively associated with human mtDNA diseases \[[@B1]\]; however, only a small percentage of these mutations were properly confirmed <http://www.mitomap.org/rimtab2.html>. In fact, the pathogenicity of some mutations is still under question due to the fact that the conclusions claimed in a substantial number of studies do not rest on solid grounds or are partially or completely flawed \[[@B2]-[@B5]\].

During this last two decades, many different techniques were designed for the screening of mtDNA pathogenic mutations, including restriction fragment length polymorphism (RFLP) analysis, heteroduplex analysis (HDA), single strand conformation polymorphisms (SSCP), etc \[[@B6]-[@B11]\]. The main disadvantage of these classical screening methods is that, due to the intrinsic nature of the techniques, many mutations usually pass unnoticed. Novel and more efficient strategies have recently been proposed that allow the screening of entire mtDNA genomes; for instance, the mismatch-specific DNA endonuclease \"Surveyor™ Nuclease\" seems to be particularly useful when the most common pathogenic mutations have been ruled out previously (e.g. \[[@B12]\]). Ideally, the gold standard of sequencing the whole genome would solve the problem; nevertheless, this strategy is labor-intensive and therefore unfeasible for routine molecular diagnosis (taking into account the capacities of standard laboratories). Screening methods are also difficult to standardize and some of them are not suitable for replication assays due to their dependence on for instance electrophoretic conditions.

Minisequencing techniques have demonstrated to be efficient in other fields of research, such as forensic and population genetics \[[@B13]-[@B18]\], but also in clinical research \[[@B19]\]. This approach, also known as single nucleotide primer extension, allows the determination of the polymorphic position by DNA polymerase addition of the ddNTP complementary to the base interrogated. The primer anneals therefore to its target DNA immediately adjacent to the SNP under scrutiny. Here we present a minisequencing multiplex design which is a rapid, sensitive and low cost assay for screening mtDNA pathogenic mutations in patients suffering mtDNA disease.

Methods
=======

Subject and SNP selection
-------------------------

Blood sample of 15 patients was sent to the Fundación Pública Galega de Medicina Xenómica located in the Hospital Clínico of Santiago de Compostela (Galicia, Spain). Six of these patients are from Galicia (northwest Spain; \[[@B20]\]), and three other patients are from southeast Spain (in the Mediterranean coast); the regional Spanish provenance of the other two patients is unknown. Four of these patients presented clinical features of an undetermined neuropathy, while the rest of the patients were analyzed under suspicion of Leber disease. Written informed consent was obtained from all patients and the study was approved by the institutional review board of the University of Santiago de Compostela (Spain). All the samples were genotyped for a set of 25 variants, 21 are confirmed pathogenic mutations related to different mtDNA diseases such as MELAS, LHON, Leigh Disease, and NARP. These mutations are distributed all around the mtDNA molecule and \'hit\' different mtDNA genes (Table [1](#T1){ref-type="table"}). All the selected mutations, with the only exception of m.3243A\>G, consist of non-synonymous substitutions (both transitions and transversion, but note that the minisequencing technique could be also suitable for interrogating indels \[[@B17]\]).

###### 

Characteristics of the mutations incorporated in our multiplex design

  **POSITIONS**   **Base change**   **Amino Acid change**   **Locus**   **Disease^1^**
  --------------- ----------------- ----------------------- ----------- --------------------------
  3243            A\>G              tRNA Leu (UUR)          MT-TL1      MELAS, DM/DMDT, CPEO, MM
  3460            G\>A              Ala\>Thr                MT-ND1      LHON
  3697            G\>A              Gly\>Arg                MT-ND1      MELAS
  3946            G\>A              Glu\>Lys                MT-ND1      MELAS
  3949            T\>C              Tyr\>Lys                MT-ND1      MELAS
  7445            A\>G              Ter\>Ter                MT-CO1      SNHL
  7445            A\>C              Ter\>Ser                MT-CO1      DEAF
  8993            T\>G              Leu\>Arg                MT-ATP6     NARP
  8993            T\>C              Leu\>Pro                MT-ATP6     NARP, Leigh Disease
  9176            T\>C              Leu\>Pro                MT-ATP6     FBSN, Leigh Disease
  9176            T\>G              Leu\>Arg                MT-ATP6     Leigh Disease
  10158           T\>C              Arg\>Pro                MT-ND3      Leigh Disease
  10191           T\>C              Arg\>Pro                MT-ND3      ESOC, Leigh-like Disease
  10663           T\>C              Val\>Ala                MT-ND4      LHON
  11777           C\>A              Arg\>Ser                MT-ND4      Leigh Disease
  11778           G\>A              Arg\>His                MT-ND4      LHON
  11832           G\>A              Trp\>Ter                MT-ND4      Exercise Intolerance
  12706           T\>C              Phe\>Leu                MT-ND5      Leigh Disease
  13513           G\>A              Asp\>Asn                MT-ND5      MELAS, Leigh Disease
  13514           A\>G              Asp\>Gly                MT-ND5      MELAS
  14459           G\>A              Ala\>Val                MT-ND6      LYDT, Leigh Disease
  14482           C\>A              Met\>Ile                MT-ND6      LHON
  14482           C\>G              Met\>Ile                MT-ND6      LHON
  14484           T\>C              Met\>Val                MT-ND6      LHON
  14487           T\>C              Met\>Val                MT-ND6      Dystonia, Leigh Disease

^1^List of some diseases where these mutations are frequently observed: CPEO: Chronic Progressive External Ophthalmoplegia; DEAF Maternally inherited DEAFness or aminoglycoside-induced DEAFness DM: Diabetes Mellitus; LDYT: Leber\'s hereditary optic neuropathy and DysTonia; LHON: Leber Hereditary Optic Neuropathy; MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes; MM: Mitochondrial Myopathy; NARP: Neurogenic muscle weakness, Ataxia, and Retinitis Pigmentosa; alternate phenotype at this locus is reported as Leigh Disease; SNHL: SensoriNeural Hearing Loss

Primer design
-------------

The primers both for PCR amplification (Table [2](#T2){ref-type="table"}) and minisequencing reaction (Table [3](#T3){ref-type="table"}) were designed to have an annealing temperature around 60°C using Primer3 software <http://frodo.wi.mit.edu/cgi-bin/primer3>. The sequence databases at the National Centre for Biotechnology Information (NCBI; <http://www.ncbi.nlm.nih.gov>) were interrogated using the online BLAST tool to test the primers against possible repetitive sequences and sequence homologies in the autosomal genome. Each primer pair for PCR amplification and each single base extension primer were selected independently and AutoDimer <http://www.cstl.nist.gov/biotech/strbase/AutoDimerHomepage/AutoDimerProgramHomepage.htm> was used to test for potential hairpin structures and primer-dimer problems.

###### 

Amplification primers

  **POSITIONS**             **FORWARD**              **REVERSE**               **SIZE (bp)**   **Final Concentration (μM)**
  ------------------------- ------------------------ ------------------------- --------------- ------------------------------
  3243                      tatacccacacccacccaag     ggccatgggtatgttgttaag     118             0.2
  3460                      ccgaacgaaaaattctaggc     gcggtgatgtagagggtgat      153             0.2
  3697                      gcctagccgtttactcaatcc    tgagattgtttggggctactgc    94              0.15
  3946/3949^1^              tagcagagaccaaccgaacc     gaagattgtagtggtgagggtgt   157             0.2
  7445                      ccctaccacacattcgaagaa    tggcttgaaaccagctttg       89              0.2
  8993                      aatgccctagcccacttctt     aggtggcctgcagtaatgtt      140             0.15
  9176                      aaatcgctgtcgccttaatc     tcattaggagggctgagagg      154             0.3
  10158/10191               tcaacaccctcctagcctta     gggtaaaaggagggcaattt      196             0.3
  10663                     acacccactccctcttagcc     ggccatatgtgttggagattg     110             0.3
  11777/11778/11832         cacgggcttacatcctcatt     gggggtaaggcgaggttag       157             0.2
  12706^1^                  tgtagcattgttcgttacatgg   agttggaataggttgttagcgg    146             0.2
  13513/13514               attggcagcctagcattagc     cagggaggtagcgatgagag      131             0.2
  14459/14482/14484/14487   ctccatcgctaaccccacta     ttctgaattttgggggaggt      170             0.4

^1^These primers were reported in \[16\]

###### 

Minisequencing primers

  **POSITIONS**   **Extension Primer^1^**                      **Length**   **Base change**   **Strand**   **Final Concentration (μM)^3^**
  --------------- -------------------------------------------- ------------ ----------------- ------------ ---------------------------------
  10158           acaactcaacggctacatagaaaaa                    25           T\>C              L            0.2
  3946            Cgaactagtctcaggcttcaacatc                    25           G\>A              L            0.2
  10663           GACTGcaatattgtgcctattgccatactag              31           T\>C              L            0.2
  3460            (GACT)~2~Ggctactacaacccttcgctgac             31           G\>A              L            0.2
  10191           (GACT)~4~agtgcggcttcgaccctata                36           T\>C              L            0.3
  14459           (GACT)~2~GACctcaggatactcctcaatagccatc        36           G\>A              L            0.3
  14484^2^        (GACT)~3~atcgctgtagtatatccaaagacaacYa        40           T\>C              L            0.5
  3243            (GACT)~4~GAacagggtttgttaagatggcag            40           A\>G              L            0.2
  11777           (GACT)~5~Gcaaactacgaacgcactcacagt            44           C\>A              L            0.2
  7445            (GACT)~5~tcgaagaacccgtatacataaaatctag        48           A\>G/C            L            0.2
  12706           (GACT)~9~gcggtaactaagattagtatggtaattagga     52           T\>C              H            0.2
  3949^2^         (GACT)~11~GAagtctcaggcttcaacatcRaa           52           T\>C              L            0.2
  14487^2^        (GACT)~7~GctgtagtatatccaaagacaaccaSca        56           T\>C              L            0.6
  13513           (GACT)~8~ttcctcacaggtttctactccaaa            56           G\>A              L            0.1
  13514           (GACT)~10~Ttgcggtttcgatgatgtgg               60           A\>G              H            0.2
  3697            (GACT)~9~CTaaactcaaactacgccctgatc            60           G\>A              L            0.2
  11778           (GACT)~9~GAgaagtccttgagagaggattatgatg        64           G\>A              H            0.3
  11832           (GACT)~8~GACtcaaactctactcccactaatagcttttt    64           G\>A              L            0.1
  9176            (GACT)~11~Gatccaagcctacgttttcacacttc         70           T\>C/G            L            0.2
  14482           (GACT)~11~gccatcgtcgctgtagtatatccaaagacaac   73           C\>A/G            L            0.6
  8993            (GACT)~13~Gcctactcattcaaccaatagccc           76           T\>G/C            L            0.2

^1^Capital letters indicate the segment of the primer belonging to the tail

^2^These primers are \'degenerated\' at the indicated position in the second column (see Material and Methods) using the IUB code

Although the simultaneous occurrence of more than one pathogenic mutation in a single individual is infrequent, it could be possible that the presence of m.14484T\>C could interfere with the genotyping of m.14487T\>G (due to their physical proximity). Therefore, in order to avoid potential artifacts due to deficient annealing, we have designed a degenerate extension primer containing a mixture of nucleotide C and T at site 14484. The same rationale applies to variation at other two positions. According to our design, m.14482C\>G mutation could interfere with the genotyping at position 14484; and the presence of m.3946G\>A could alter the genotyping of m.3949T\>C; we therefore designed another extension degenerate primer containing C and G at site 14482 and another additional extension degenerated primer carrying G and A at site 3946 (Table [3](#T3){ref-type="table"}).

PCR multiplex amplification
---------------------------

The SNPs were PCR amplified in 13 amplicons with sizes ranging from 89 and 196 bp. The amplicons are deliberately designed to be small in order to facilitate the analysis of samples that are highly degraded or with low quantity of DNA. Some amplicons encompass several SNPs (Table [1](#T1){ref-type="table"}). We performed multiplex reaction using 5 ng of DNA template and PCR master mix of QIAGEN Kit Multiplex PCR (Qiagen, Hilden, Germany), amplification primers and their final concentrations are in Table [2](#T2){ref-type="table"}. Amplification was carried out in a 9700 Thermocycler (Applied Biosystems, Foster City, CA, USA). After a 95°C pre-incubation step for 15 minutes, PCR was performed in a total of 30 cycles using the following conditions: 94°C denaturation for 30 seconds, annealing at 60°C for 90 seconds and extension at 72°C during 90 seconds, followed by a 15 minutes of final extension at 72°C and 4°C until removed from thermocycler. PCR products were checked by polyacrylamide gel electrophoresis (T9, C5) visualized by silver staining.

Minisequencing reaction
-----------------------

Previous to minisequening reaction, PCR products are treated with ExoSAP-IT (Amershan Bioscences, Uppsala, Sweden) to remove excess primers and un-incorporated dNTPs: 3 μl of PCR product was incubated with 1.5 μl for 15 minutes at 37°C followed by 15 minutes at 80°C for enzyme inactivation. Minisequencing reaction is performed using SNaPshot™ Kit (AB). We modified the length of the primers (between 25 and 76 bp) by the addition of non-homologous tails, poly(dGACT) added at the 5\'- end (Table [3](#T3){ref-type="table"}). The minisequencing reaction was carried out in a total volume of 10 μl comprising 3 μl of the SNaPshot™ Kit (AB), 1.5 μl PCR product, 1.5 μl of extension primers mix (final concentrations are between 0.1 and 0.6 μM) (Table [3](#T3){ref-type="table"}), and water up to 10 μl. The reaction was performed in a 9700 Thermocycler (AB) following the recommendations of the manufacturer: 25 cycles of denaturation at 96°C for 10 seconds, annealing at 50°C for 5 seconds and extension at 60°C during 30 seconds. Un-incorporated ddNTPs are eliminated with a treatment with SAP (Amershan Bioscences). The final volume (10 μl) was treated with 1 μl of SAP for 60 minutes at 37°C followed by 15 minutes at 80°C for enzyme inactivation.

The minisequencing products (1.5 μl) were mixed with 10 μl of HiDi™ formamide (AB) and 0.25 μl of GeneScan -120 LIZ (AB) and capillary electrophoresis was undertaken on an ABI PRISM 3130 ×l Genetic Analyzer (AB). The data was analyzed using GeneMapper™ 3.7 Software (AB).

Sequencing reaction
-------------------

All the 13 amplicons were sequenced in an ABI PRISM 3130 ×l Genetic Analyzer (AB) for all the patients with the aim of corroborating the mutations observed with the minisequencing assay. Technical details regarding sequencing reaction are given in \[[@B17]\].

Results
=======

Only 13 amplicons are needed to interrogate the selected 25 variants. This is because (i) \'neighbouring\' variants are genotyped using different minisequencing probes annealing at the same amplicon, and (ii) different minisequencing probes were designed to genotype different pathogenic substitutions occurring at the same mtDNA site. Therefore, for each of the sites 7445, 9176, and 14482, there are two common mtDNA mutations described in the literature as pathogenic, the most common one for each of these three sites was already confirmed (m.7445A\>G, m.9176T\>C, and m.14482C\>G), while the alternative one (m.7445A\>C, m.9176T\>G, and m.14482C\>A) still bears the status of \'provisional\' in MITOMAP. In addition, position 8993 has two already confirmed variants, namely, T to C and T to G substitutions.

We did not observe mutations in four patients presenting neurological symptoms. On the other hand, a pathogenic mutation was found for each of the other 11 patients with clinical suspicion of Leber disease (Table [4](#T4){ref-type="table"}). All the mutations were confirmed by sequencing and were observed as homoplasmic using both minisequencing and automatic sequencing (Figure [1](#F1){ref-type="fig"}). Nine patients carried mutation m.11778G\>A whereas two patients carried m.14484T\>C.

![Electropherograms showing (a) two different SNaPshot profiles carrying mutations m.11778G\>A and m.14484T\>C; rCRS \[50\] electropherogram is also shown indicating the whole set of mutations tested with the SNaPshot reaction; and (b) forward and reverse sequence electropherograms for these same mutations.](1471-2350-9-26-1){#F1}

###### 

Patient samples analyzed in the present study

                 **3**   **3**   **3**   **3**   **3**   **7**   **8**   **9**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   
  ------ ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----------
  \#1    I-111   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#2    D-112   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      11812
  \#3    I-138   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      10172
  \#4    F-393   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#5    C-436   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      
  \#6    B-703   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      
  \#7    B-900   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#8    B-901   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#9    D-992   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      
  \#10   1586    \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#11   5699    \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **C**   \-      12696
  \#12   5869    \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **C**   \-      12696
  \#13   G-495   \-      \-      \-      \-      \-      \-      \-      \-      \-      \-              \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      
  \#14   7218    \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      
  \#15   9615    \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      \-      **A**   \-      \-      \-      \-      \-      \-      \-      \-      12705C/T

^1^Variants detected by automatic sequencing (putatively unrelated to the disease outcome). Position 12705 is heteroplasmic C/T.

The two carriers of m.14484T\>C lived in the same geographic (relatively isolated) village (namely, Burela) in the northern cost of Galicia \[[@B20],[@B21]\]. These samples were submitted at different times to the laboratory and according to the carriers, their families were unrelated. Both patients share also the transition m.12696T\>C (observed by sequencing), indicating that these individuals could actually share some recent common ancestor. The m.12696T\>C transition is not a frequent variant in Europe and likely constitutes a diagnostic variant of a minor HV1 sub-lineage (although this variant is also recurrent in at least other eight non-European haplogroups, including haplogroup J, see below): it appears in at least six haplogroup HV1 complete genomes (see for instance \[[@B22],[@B23]\]). Therefore, the m.14484T\>C transition could represent a founder pathogenic mutation responsible of Leber disease in Galicia (as it is the case of a wide spectrum of different non-mtDNA diseases \[[@B24],[@B25]\].

In order to further investigate this hypothesis, we additionally genotyped all the Galician samples for a set of haplogroup diagnostic mtDNA SNPs following \[[@B16]\] (Table [5](#T5){ref-type="table"}). The two carriers of m.14484T\>C but also two other Galician samples carrying m.11778G\>A could be allocated to haplogroup J (and not to HV1 as it could be inferred by the presence of m.12696T\>C). Therefore, the observation of the m.14484T\>C mutation in two unrelated patients from the above mentioned small Galician village could just reflect the already reported high incidence of Leber mutations within haplogroup J \[[@B26],[@B27]\]. In fact, we also observe that the frequency of haplogroup J in healthy unrelated Galician individuals is \~14.7% \[[@B20],[@B21],[@B28]\] but it occurs in four out of our six Galician patients (\~66.7%); the difference in prevalence is statistically significant (Fisher\'s Exact test, *P*-value \< 0.006)

###### 

Coding SNP and haplogroup status of the Galician patients

                                                                                         **1**   **1**   **1**   **1**   **1**   **1**   **1**   **1**   
  ------ ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----
  \#3    I-138   **-**   **-**   **C**   **-**   **-**   **-**   **-**   **-**   **T**   **G**   **-**   **-**   **-**   **-**   **-**   **-**   **T**   J
  \#4    F-393   **-**   **-**   **C**   **-**   **-**   **-**   **-**   **-**   **T**   **G**   **-**   **-**   **-**   **-**   **-**   **-**   **T**   J
  \#10   1586    **-**   **-**   **-**   **-**   **-**   **-**   **-**   **G**   **-**   **-**   **-**   **-**   **-**   **-**   **-**   **-**   **-**   H3
  \#11   5699    **-**   **-**   **C**   **-**   **-**   **-**   **-**   **-**   **T**   **G**   **-**   **-**   **-**   **-**   **-**   **-**   **T**   J
  \#12   5869    **-**   **-**   **C**   **-**   **-**   **-**   **-**   **-**   **T**   **G**   **-**   **-**   **-**   **-**   **-**   **-**   **T**   J
  \#13   G-495   **-**   **-**   **-**   **-**   **-**   **-**   **-**   **-**   **T**   **-**   **-**   **-**   **-**   **G**   **-**   **-**   **T**   U

HG = haplogroup

Other variants were also observed by sequencing analysis in m.11778G\>A carriers. For instance, the transition A11812G is diagnostic of haplogroup T2 and G10172A identifies haplogroup J2b; these variants also appear sporadically in other haplogroup backgrounds. In addition, we observe a heteroplasmy at position 12705; transition C12705T is a well-known diagnostic site that (together with T16223C) leads from macro-haplogroup N to R.

Mixtures of two different DNA bearing different SNP profiles were carried out in order to simulate mtDNA heteroplasmy, a common state in mtDNA disease patients. As shown in Figure [2](#F2){ref-type="fig"}, the minisequencing assay is perfectly able to detect the mixtures at different proportions. According to \[[@B29]\] \"*the single most important disadvantage of the SNaPshot is that it seems less accurate than conventional PCR-RFLP analysis for*\[detecting\] *high levels of mutant mtDNA*\". Our results however indicate that the ability of SNaPshot for detecting heteroplasmy is actually equivalent to standard sequencing. Some fluorocromes \'project\' more intensity in the electropherogram than other (as it also occurs with some sequencing chemistries), and this should be taking into account when quantifying the real proportions of wild:mutant DNA (heteroplasmy).

![Partial electropherograms showing the performance of the SNaPshot assay with mixtures of wild:mutant DNAs. Numbers in the top indicate the percentages of wild:mutant mixture.](1471-2350-9-26-2){#F2}

Although our primer design take into account the proximity of two pathologic mutations, it is not possible to consider all the potential polymorphisms that could hit within the annealing segments, and therefore alter the PCR efficacy (and in the worst of the cases, produce an artefact related to e.g. the spurious amplification of a NUMT; see below). This is however an universal problem affecting most of the genotyping techniques (including RFLP and sequencing) and therefore, the expert should be always alert under the possibility of false negative results. The experience of previous SNaPshot designs \[[@B16],[@B18],[@B30]\] indicates however that the method is robust under the presence of polymorphisms.

Finally, the multiplex reaction was also tested in 102 control individuals. There were not false positives in this control sample and the SNP-minisequencing profiles were phylogenetically concordant \[[@B31],[@B32]\].

Discussion
==========

MtDNA mutations are responsible for various clinical features, which often make diagnosis a considerable challenge. Since the mitochondria constitute the energetic \'factory\' of all nucleated cells, mtDNA diseases affect many tissues with variable clinical outcomes. When searching the Mitomap database for pathogenic mtDNA mutations, many of them harbour the status of \'provisional\', while some other stated as \'confirmed\'; among the later, some were recently questioned \[[@B2],[@B33],[@B34]\]. We here selected a total of 25 mutations, 21 of them were confirmed as pathogenic in common mtDNA diseases in multiple independent studies and considering different criteria, including the score system proposed by \[[@B33]\] (see also \[[@B35]\]) and also the complementary phylogenetic approach \[[@B2]\]. For instance, we included all the MTND gene mutations evaluated with the complex I pathogenicity scoring system of \[[@B33]\] (see their Table [2](#T2){ref-type="table"}) and reaching the 16 top values (≥ 30). Apart from the 21 confirmed mutations included in the design, the remaining four mutations were additionally included because they occur at lower frequencies at four of the initially 21 selected positions.

Among the selected mutations, we have the transition m.3243A\>G which is a typical cause of MELAS \[[@B36]\] and MIDD \[[@B37]\]; transition m.8993T\>G, responsible of a number of patients suffering NARP \[[@B38]\] and MILS \[[@B39]\]; transitions m.3460G\>A, m.11778G\>A, m.14484T\>C, which are common causal mutations in LHON patients \[[@B40],[@B41]\], etc. (see \[[@B42]\] for a review). It can be tentatively said that the selected SNPs actually cover an ample spectra of the fully confirmed causal mutations in the most common mtDNA diseases. For instance, according to \[[@B43]\], the prevalence of m.3243A\>G is about 1 in 6,135 in the general (European) population; see also \[[@B44]\]. It is also worth to mention that it is straightforward to add mutations to our initial multiplex design because SNaPshot minisequencing is very flexible in this regard \[[@B17]\].

Conclusion
==========

The minisequencing reaction presented here detected 11 mutations in an easy and straightforward manner in 11 different patients with clinical suspicion of Leber disease. All the mutations and their homoplasmic status were finally confirmed by automatic sequencing. We did not observed false positives in a substantial number of controls. We also simulated heteroplasmic states by mixing wild:mutant DNAs; the minisequencing technique demonstrates a good performance in detecting at least mixtures up to 1:10.

The multiplex reaction shows various advantages in the clinical field with respect to other techniques (see \[[@B17]\] for more details). For instance, the primers were designed in order to obtain amplicons of size ranging 89--196, a feature of special interest in a clinical context where often the laboratories have to deal with suboptimum samples containing low amounts of DNA or highly degraded DNA (paraphine imbibed samples, biopsies, etc.) as it is also the case with forensic samples \[[@B13]\]. Finally, we estimate that the cost of genotyping 25 SNPs is at least 20 times lower than the cost of RFLP genotyping (considering genotyping of one mutation at the time), and it can be done in less than three hours (including post-PCR purification, minisequencing reaction, purification of minisequencing products, electrophoresis, and documentation) for as many samples as the number of capillaries of the automatic sequencer.

Also important is the fact that minisequencing is robust respect potential artefacts related to false positives at NUMTs (author\'s unpublished data). Multiplex genotyping also prevents from artificial recombination; the later is a kind of common artefact that more easily arise as more independent fragments are genotyped for the same sample \[[@B31],[@B32],[@B45]-[@B49]\].

Finally, the screening method presented here should not be considered as a substitute of complete genome sequencing. The latter should be performed when the minisequencing screening (or the use of other alternative strategies) fails to identify the causal mutation.
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